201150-66-5

Basic information

• Product Name: Silane, [(5-bromo-2-methoxyphenyl)methoxy](1,1-dimethylethyl)dimethyl-
• CAS NO: 201150-66-5
• Molecular Formula: C14H23BrO2Si
• Molecular Weight: 331.325
• Mol File: 201150-66-5.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Silane, [(5-bromo-2-methoxyphenyl)methoxy](1,1-dimethylethyl)dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, [(5-bromo-2-methoxyphenyl)methoxy](1,1-dimethylethyl)dimethyl-(201150-66-5)
• EPA Substance Registry System: Silane, [(5-bromo-2-methoxyphenyl)methoxy](1,1-dimethylethyl)dimethyl-(201150-66-5)

Safety Data

• Hazardous Substances Data: 201150-66-5(Hazardous Substances Data)

Upstream product

• 288-32-4 1H-imidazole 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 25016-01-7 5-bromo-2-methoxybenzaldehyde 
• 361162-16-5 tert-butyl-(2-methoxy-benzyloxy)-dimethyl-silane 
• 80866-82-6 5-bromo-2-methoxy-benzyl alcohol 
• 74-88-4 methyl iodide 

Downstream Products

• 916441-94-6 2-(3-(hydroxymethyl)-4-methoxyphenyl)-2-methylpropanenitrile 
• 1396507-32-6 C₂₄H₃₉⁽¹⁸⁾FN₂O₂Si 
• 1396507-21-3 (S)-N-((1-allylpyrrolidin-2-yl)methyl)-5-(di-tert-butylfluorosilyl)-2-methoxybenzamide 
• 1396506-38-9 5-(di-tert-butylfluorosilyl)-2-methoxybenzoic acid 
• 1396506-79-8 5-(di-tert-butylfluorosilyl)-2-methoxybenzaldehyde 
• 1396506-75-4 (5-(di-tert-butylfluorosilyl)-2-methoxyphenyl)methanol 
• 1396506-65-2 di-tert-butyl(3-((tert-butyldimethylsilyloxy)methyl)-4-methoxyphenyl)fluorosilane 
• 202822-81-9 2-methoxy-5-(1-methyl-1H-imidazol-2-yl)benzenemethanol 

Relevant articles and documents

Substituted Pyrrolidines and Methods of Use

The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

T-Bu2SiF-derivatized D2-receptor ligands: The first SiFA-containing small molecule radiotracers for target-specific PET-imaging

The synthesis, radiolabeling and in vitro evaluation of new silicon-fluoride acceptor (SiFA) derivatized D2-receptor ligands is reported. The SiFA-technology simplifies the introduction of fluorine-18 into target specific biomolecules for Positron-Emission-Tomography (PET). However, one of the remaining challenges, especially for small molecules such as receptor-ligands, is the bulkiness of the SiFA-moiety. We therefore synthesized four Fallypride SiFA-conjugates derivatized either directly at the benzoic acid ring system (SiFA-DMFP, SiFA-FP, SiFA-DDMFP) or at the butyl-side chain (SiFA-M-FP) and tested their receptor affinities. We found D2-receptor affinities for all compounds in the nanomolar range (Ki(SiFA-DMFP) = 13.6 nM, Ki(SiFA-FP) = 33.0 nM, Ki(SiFA-DDMFP) = 62.7 nM and Ki(SiFA-M-FP) = 4.21 nM). The radiofluorination showed highest yields when 10 nmol of the precursors were reacted with [18F]fluoride/TBAHCO3 in acetonitrile. After a reversed phased cartridge purification the desired products could be isolated as an injectable solution after only 10 min synthesis time with radiochemical yields (RCY) of more than 40% in the case of SiFA-DMFP resulting in specific activities >41 GBq/μmol (>1,100 Ci/mmol). Furthermore, the radiolabeled products were shown to be stable in the injectable solutions, as well as in human plasma, for at least 90 min.

Inhibitors of c-Jun N-terminal kinases

The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.